RTKs and MAPK Signaling - Biochemistry

1. In a cell culture experiment, researchers transfect cells with a mutant EGFR (epidermal growth factor receptor) that lacks the kinase domain but retains the extracellular ligand-binding domain and transmembrane region. When these cells are stimulated with EGF, which outcome would be most expected regarding MAPK pathway activation?
   Answer: No MAPK activation occurs because autophosphorylation of receptor tyrosine residues is essential for creating docking sites for downstream signaling proteins. RTK signaling requires autophosphorylation of specific tyrosine residues in the receptor's cytoplasmic tail to create docking sites for adaptor proteins like Grb2 and SOS. Without the kinase domain, autophosphorylation cannot occur, preventing recruitment of downstream signaling components and blocking MAPK pathway activation. Option A is wrong because dimerization alone is insufficient - phosphorylation is required. Option B is incorrect because adaptor protein binding specifically requires phosphotyrosine residues. Option D is wrong because without kinase activity, there would be no initial signal to sustain.
2. Sodium orthovanadate is a general inhibitor of protein tyrosine phosphatases (PTPs). If cells are treated with this inhibitor and then briefly stimulated with a growth factor, what is the most likely outcome for the RTK signaling pathway?
   Answer: The autophosphorylation of the RTK and phosphorylation of downstream targets will be more robust and prolonged. The correct answer is B. Protein kinases add phosphate groups to activate signaling components, while protein phosphatases remove them to terminate the signal. Protein tyrosine phosphatases (PTPs) specifically remove phosphates from tyrosine residues. By inhibiting PTPs, sodium orthovanadate removes the 'off switch' for tyrosine phosphorylation. This means that once the RTK is autophosphorylated upon ligand binding, it will remain phosphorylated (and thus active) for a longer period. This leads to a more sustained and stronger signal throughout the pathway. Choice A is incorrect; dimerization is ligand-induced. Choice C is incorrect; Ras activation is mediated by a GEF, not a phosphatase. Choice D is incorrect because vanadate inhibits phosphatases, which would indirectly lead to more kinase activity, not less.
3. A researcher is studying a novel growth factor receptor that belongs to the RTK family. When cells are treated with the growth factor, receptor autophosphorylation occurs within 2 minutes, followed by activation of downstream MAPK signaling. However, when cells are pretreated with a specific tyrosine phosphatase inhibitor before growth factor addition, the MAPK response is significantly enhanced and prolonged. What is the most likely explanation for this observation?
   Answer: The phosphatase inhibitor prevents dephosphorylation of activated signaling intermediates, sustaining phosphorylation cascades and extending MAPK pathway responses. Tyrosine phosphatases normally terminate RTK and MAPK signaling by dephosphorylating activated kinases and adaptor proteins in the pathway. Inhibiting these phosphatases would prevent the normal 'off' signal, leading to sustained phosphorylation of pathway components and prolonged MAPK activation. Option A is incorrect because phosphatases don't prevent dimerization - they act on phosphorylated residues. Option B is wrong because phosphatases don't directly control receptor internalization. Option D is incorrect because phosphatases don't affect ligand-receptor binding affinity.
4. Researchers are investigating cross-talk between RTK/MAPK signaling and other pathways. They discover that activation of protein kinase A (PKA) by cAMP can phosphorylate Raf at a specific serine residue, and this phosphorylation inhibits Raf's ability to phosphorylate MEK. In cells simultaneously stimulated with both a growth factor (activating RTK/MAPK) and forskolin (activating adenylyl cyclase/cAMP/PKA), what pattern of ERK activation would be most expected over time?
   Answer: Initial strong ERK activation followed by rapid decline as PKA activation increases, then sustained low-level ERK activity reflecting the inhibited but not completely blocked MAPK pathway. Growth factor stimulation would initially activate RTK-Raf-MEK-ERK signaling. As forskolin simultaneously activates adenylyl cyclase, rising cAMP levels activate PKA, which then phosphorylates and inhibits Raf. This creates a pattern of initial ERK activation that declines as PKA activity increases, but some ERK activity would remain because PKA inhibition is typically partial, not complete. Option B is incorrect because both signals start simultaneously. Option C is wrong because there's no mechanism described for oscillations. Option D is incorrect because PKA phosphorylation inhibits rather than primes Raf activity.
5. A research team discovers that a particular cell type expresses two different RTKs (RTK-A and RTK-B) that both activate the same MAPK pathway. RTK-A has a high affinity for its ligand (Kd = 1 nM) but weak kinase activity, while RTK-B has lower affinity (Kd = 50 nM) but strong kinase activity. If cells are exposed to a mixture containing 10 nM of ligand A and 10 nM of ligand B simultaneously, which scenario best describes the expected MAPK response?
   Answer: The responses will be additive but RTK-A will contribute more because at 10 nM ligand concentration, RTK-A achieves higher fractional occupancy than RTK-B. At 10 nM ligand concentrations: RTK-A (Kd=1 nM) will have ~91% occupancy (10/(10+1)), while RTK-B (Kd=50 nM) will have ~17% occupancy (10/(10+50)). Even though RTK-B has stronger kinase activity per receptor, the much higher occupancy of RTK-A means more total activated receptors, likely resulting in RTK-A contributing more to the overall response. The responses would be additive since both activate the same pathway. Option A is incorrect because it ignores the kinase activity differences. Option B underestimates the importance of receptor occupancy. Option C is wrong because the combinations don't perfectly balance at these concentrations.
6. A pharmaceutical company is developing an anti-cancer drug that specifically inhibits MEK (MAPKK) in the MAPK pathway. In clinical trials, some patients show initial tumor regression, but after several weeks, tumors begin growing again despite continued drug treatment. Molecular analysis reveals that Raf (MAPKKK) expression has increased significantly in resistant tumor cells. What is the most likely mechanism underlying this drug resistance?
   Answer: Elevated Raf levels lead to stronger MEK activation signals that can outcompete the inhibitor for MEK binding sites, restoring pathway function through mass action effects. In kinase inhibitor resistance, increased expression of upstream kinases can overcome competitive inhibition through mass action - higher Raf levels produce more activated Raf molecules that can phosphorylate and activate more MEK molecules, some of which may escape inhibitor binding and restore downstream ERK activation. Option A is incorrect because MEK specifically activates ERK, and there are no major alternative pathways that bypass this step. Option C is wrong because ERK is primarily activated by MEK - there are no significant MEK-independent pathways to ERK. Option D is incorrect because increased Raf wouldn't enhance feedback inhibition, and this mechanism doesn't explain resistance to MEK inhibition.
7. A cell line co-expresses two different mutant forms of an RTK. Mutant A has an intact ligand-binding domain and a functional kinase domain, but its own cytoplasmic tyrosine residues are mutated to alanine. Mutant B has a defective, inactive kinase domain, but its cytoplasmic tyrosine residues are intact. Assuming ligand binding can induce the formation of A-B heterodimers, what will be the outcome for downstream signaling?
   Answer: Signaling will occur because the kinase domain of Mutant A will phosphorylate the tyrosine residues on Mutant B. When analyzing receptor tyrosine kinase (RTK) signaling, remember that successful signal transduction requires both kinase activity to phosphorylate tyrosines AND available tyrosine residues to serve as phosphorylation targets. The key insight here is that these functions can occur in trans between different receptor molecules within a dimer. Upon ligand binding, Mutant A and Mutant B form heterodimers. Mutant A contributes a functional kinase domain, while Mutant B provides intact cytoplasmic tyrosine residues. The active kinase domain of Mutant A can phosphorylate the tyrosine residues on Mutant B in trans, creating phosphotyrosine docking sites for downstream signaling proteins like SH2 domain-containing adapters. This complementation allows the signaling pathway to proceed normally. Option A incorrectly assumes that each individual receptor must be fully functional, missing the concept of trans-phosphorylation between dimeric partners. Option B fails to recognize that Mutant B participates crucially by providing phosphorylation substrates, even though its kinase domain is inactive. Option C misunderstands the system entirely—ligand binding is still required for dimerization and kinase activation, and there's nothing constitutive about this arrangement. The correct answer is D because trans-phosphorylation between receptor subunits is a fundamental mechanism in RTK signaling that allows functional complementation. Study tip: For RTK questions, always consider whether the essential components (ligand binding, kinase activity, and phosphorylatable tyrosines) can be distributed across multiple receptor molecules in a complex. Trans-phosphorylation is a recurring theme in receptor biology.
8. The Ras G12V mutation is a common oncogenic mutation that renders the protein constitutively active. Biochemically, this mutation impairs Ras's ability to hydrolyze GTP to GDP, even in the presence of a GTPase-activating protein (GAP). Which statement best explains why this leads to uncontrolled cell proliferation?
   Answer: By being trapped in the GTP-bound state, Ras continuously activates its downstream effectors, regardless of upstream signals. The correct answer is D. Ras functions as a molecular switch, being 'on' when bound to GTP and 'off' when bound to GDP. The G12V mutation specifically cripples the GTPase activity, which is the 'off' switch. By being unable to hydrolyze GTP to GDP, the protein becomes trapped in the active, GTP-bound conformation. This leads to persistent, unregulated stimulation of downstream effectors like the Raf kinase, driving cell proliferation even in the absence of growth factors. Choice A is incorrect because the GDP-bound state is the inactive form. Choice B is incorrect because the primary defect is in GTP hydrolysis (the 'off' switch), not GTP loading (the 'on' switch). Choice C is incorrect because Ras must be localized to the membrane to function correctly.
9. In a cell line with a normally functioning Epidermal Growth Factor Receptor (EGFR) and MAPK pathway, a loss-of-function mutation is identified in the gene encoding Ras-GAP (GTPase Activating Protein). How would this mutation be expected to alter the cellular response to a brief pulse of EGF stimulation?
   Answer: The signal will be prolonged because the intrinsic GTPase activity of Ras is slow, keeping it in the active GTP-bound state for longer. The correct answer is C. Ras has a slow intrinsic GTPase activity that hydrolyzes GTP to GDP, turning itself off. GTPase-Activating Proteins (GAPs) dramatically accelerate this process, acting as the primary 'off switch'. A loss-of-function mutation in Ras-GAP means this 'off switch' is broken. Therefore, upon activation by a GEF, Ras will remain in its active, GTP-bound state for a much longer period, leading to a prolonged downstream signal. Choice A is incorrect because GAPs accelerate, not inhibit, GTP hydrolysis. Choice B is incorrect because Ras activation by GEFs is unaffected; the inactivation step is what is impaired. Choice D is incorrect because GAP's role is in deactivation, not in mediating the interaction with the downstream effector Raf.
10. In studying MAPK pathway regulation, researchers notice that prolonged growth factor stimulation (>4 hours) leads to decreased ERK activity despite continued receptor activation. Further investigation reveals increased expression of dual-specificity phosphatases (DUSPs) during this time period. However, when cells are treated with a protein synthesis inhibitor along with the growth factor, ERK activity remains elevated throughout the treatment period. What is the most likely explanation for this observation?
    Answer: The protein synthesis inhibitor blocks production of negative regulatory proteins including DUSPs, preventing the normal desensitization response and maintaining sustained ERK phosphorylation levels. The data shows that prolonged stimulation normally induces DUSP expression, which dephosphorylates and inactivates ERK (negative feedback). When protein synthesis is blocked, DUSPs cannot be produced, preventing this negative feedback and allowing ERK to remain active. This is a classic example of how cells use induced phosphatase expression to terminate prolonged MAPK signaling. Option A is incorrect because protein synthesis inhibition would block DUSP production, not degradation. Option C is wrong because the effect is specifically about blocking DUSP synthesis, not general metabolic effects. Option D doesn't explain the DUSP observation and focuses on receptor stability rather than pathway regulation.
11. In some RTK pathways, activated ERK can phosphorylate and inhibit Sos, the guanine nucleotide exchange factor (GEF) for Ras. This is a form of negative feedback. A cell line has a mutant form of Sos that cannot be phosphorylated by ERK but is otherwise fully functional. How would the signaling dynamics in this cell line differ from a wild-type cell upon growth factor stimulation?
    Answer: The duration and overall intensity of MAPK pathway activation will be increased in the mutant cell line. The correct answer is C. The described mechanism is a negative feedback loop: the pathway's output (active ERK) inhibits an early step (Sos activity). In a wild-type cell, this feedback helps to attenuate the signal and turn it off after an appropriate duration. In the mutant cell line, this feedback mechanism is broken because Sos cannot be inhibited by ERK. As a result, Sos will remain active for longer, leading to prolonged activation of Ras and the entire downstream MAPK cascade. This results in a signal that is stronger (higher integrated intensity) and more sustained. Choice A is incorrect because the initial activation would be normal. Choice B is incorrect because the lack of negative feedback would lead to a higher, not lower, signal. Choice D is incorrect as the stem specifies the mutant is otherwise fully functional.
12. MEK is a dual-specificity kinase that phosphorylates its substrate, ERK, on both a threonine and a tyrosine residue for full activation. MEK itself is activated by phosphorylation on two serine residues by Raf. A mutant form of MEK is engineered in which the two serine residues targeted by Raf are replaced by glutamate. What is the likely activity of this mutant MEK?
    Answer: It will be constitutively active because the negative charges of the glutamate residues mimic phosphorylation. When you encounter questions about protein phosphorylation and kinase regulation, focus on how phosphate groups alter protein structure and activity through electrostatic interactions. Phosphorylation typically adds negative charges that can induce conformational changes leading to activation or deactivation. MEK requires phosphorylation on two serine residues by Raf for activation. The key insight here is understanding phosphomimetic mutations – amino acid substitutions that mimic the electrostatic effects of phosphorylation. Glutamate residues carry negative charges at physiological pH, similar to phosphate groups. When the two serine residues are replaced with glutamate, these negative charges simulate the phosphorylated state, likely keeping MEK in its active conformation without requiring Raf phosphorylation. This makes the mutant MEK constitutively active, supporting answer A. Answer B is incorrect because the question isn't about whether glutamate can be phosphorylated – it's about whether glutamate can functionally replace phosphoserine. Answer C misunderstands the mutation's effect; replacing serine residues in MEK's activation sites with glutamate wouldn't alter MEK's dual-specificity toward ERK's threonine and tyrosine residues. Answer D is wrong because this mutant MEK wouldn't bind Raf (it doesn't need Raf activation) or act as a dominant negative. Remember that phosphomimetic mutations using acidic amino acids (glutamate, aspartate) are common experimental tools to study constitutively active proteins. When you see serine/threonine→glutamate substitutions in kinase regulation questions, think "mimicking phosphorylation" rather than "preventing phosphorylation."
13. A cell expressing a wild-type RTK-MAPK pathway is treated with a high concentration of a non-hydrolyzable ATP analog, γ-S-ATP. The cells are then stimulated with a growth factor. Which of the following proteins would be found in a thiophosphorylated state, but would be unable to activate its immediate downstream target?
    Answer: MEK (MAPKK), as it requires ATP hydrolysis to phosphorylate its substrate, ERK. The correct answer is C. This question requires analyzing the flow of the kinase cascade. 1) The RTK will use γ-S-ATP to thiophosphorylate itself. 2) This will recruit Grb2/Sos and activate Ras (which uses GTP, not ATP). 3) Active Ras will activate Raf. 4) Raf, a kinase, will use γ-S-ATP to thiophosphorylate its substrate, MEK. Now, MEK is thiophosphorylated. 5) For MEK to act as a kinase and phosphorylate ERK, it needs to bind and hydrolyze ATP. Since only the non-hydrolyzable analog is available, MEK cannot transfer a phosphate to ERK. Therefore, MEK becomes thiophosphorylated but cannot activate its target. Choice A is incorrect because thiophosphorylated RTKs can still recruit SH2-domain proteins. Choice B is incorrect because Ras is a G-protein activated by GTP binding, not phosphorylation. Choice D is incorrect because ERK will not become thiophosphorylated at all, as its activator (MEK) is stalled.
14. A specific inhibitor of MEK's kinase activity is added to cultured cells that are then stimulated with a growth factor. After stimulation in the presence of the inhibitor, which of the following correctly describes the expected phosphorylation state of key signaling proteins?
    Answer: Raf will be phosphorylated and active, but ERK will be in an unphosphorylated and inactive state. The correct answer is B. The MAPK cascade proceeds in the order Ras → Raf → MEK → ERK, where each component activates the next via phosphorylation (except for Ras activating Raf). An inhibitor of MEK's kinase activity will block the step where MEK phosphorylates ERK. Therefore, the signal will propagate normally up to MEK. Ras will activate Raf, and Raf will phosphorylate and activate MEK. However, since MEK's enzymatic activity is inhibited, it cannot phosphorylate ERK. As a result, Raf will be active (and phosphorylated), but ERK will remain inactive (and unphosphorylated). Choice A is incorrect because Raf is upstream of the block and will be activated. Choice C is incorrect because the inhibitor prevents MEK from phosphorylating ERK. Choice D incorrectly inverts the pathway's order.
15. In cancer research, scientists observe that certain tumor cells have a point mutation in Ras that reduces its intrinsic GTPase activity by 90% while maintaining normal GTP binding and effector interaction capabilities. Compared to normal cells, how would this mutation most likely affect the MAPK pathway response to brief (5-minute) growth factor stimulation?
    Answer: The mutation would cause normal initial MAPK activation but dramatically prolonged ERK phosphorylation because mutant Ras remains in the active GTP-bound state much longer than normal. When you encounter questions about Ras mutations in cancer, focus on understanding the normal Ras cycle and how disruptions affect signal duration rather than signal initiation. Ras proteins function as molecular switches that cycle between active (GTP-bound) and inactive (GDP-bound) states. Upon growth factor stimulation, Ras exchanges GDP for GTP, becoming active and recruiting downstream effectors like RAF to initiate the MAPK cascade. The signal is terminated when Ras hydrolyzes GTP back to GDP through its intrinsic GTPase activity. This mutation reduces GTPase activity by 90% while preserving GTP binding and effector interactions. This means Ras can still become activated normally when growth factors stimulate GTP binding, and it can still interact with downstream proteins like RAF. However, once activated, the mutant Ras remains "stuck" in the GTP-bound state much longer because it cannot efficiently hydrolyze GTP to GDP. This leads to normal initial MAPK activation followed by dramatically prolonged ERK phosphorylation, making answer A correct. Answer B is wrong because the mutation doesn't prevent the GDP→GTP exchange needed for activation. Answer C is incorrect because the mutation doesn't enhance GTP binding or effector interactions—these remain normal. Answer D is flawed because while GAPs do assist Ras inactivation, they work by enhancing the intrinsic GTPase activity, which is severely compromised in this mutant. Study tip: Remember that oncogenic Ras mutations typically cause prolonged signaling rather than preventing or enhancing signal initiation—it's about getting stuck "on," not turning on stronger.
16. A patient with melanoma has a V600E mutation in the B-Raf gene, leading to a constitutively active B-Raf kinase. They are treated with a drug that is a highly specific inhibitor of the RTK upstream of the MAPK pathway. Which of the following best predicts the patient's response to this drug therapy?
    Answer: The therapy will be ineffective because the oncogenic signal originates from a point downstream of the drug's target. When analyzing cancer drug therapies, you need to map out the signal transduction pathway and identify where the mutation occurs relative to where the drug acts. This determines whether blocking upstream signals can affect downstream oncogenic activity. The MAPK pathway flows: RTK → Ras → B-Raf → MEK → ERK. In this patient, the V600E mutation makes B-Raf constitutively active, meaning it no longer requires upstream activation signals to function. The drug targets the RTK at the very beginning of this cascade. Since the oncogenic signal originates from the mutated B-Raf protein itself, blocking the RTK upstream cannot shut down the aberrant signaling. The mutant B-Raf will continue phosphorylating MEK regardless of RTK status, making the therapy ineffective. This makes choice A correct. Choice B incorrectly assumes that B-Raf still requires Ras activation. While normal B-Raf does need Ras, the V600E mutation bypasses this requirement entirely. Choice C suggests allosteric inhibition between the RTK inhibitor and B-Raf, but these proteins don't interact directly—they're separated by multiple pathway steps. Choice D focuses on MEK levels and alternative pathways, but the primary issue isn't pathway redundancy; it's that the oncogenic signal originates downstream of the drug target. Remember this principle: when evaluating targeted cancer therapies, always trace where the oncogenic mutation sits in the pathway relative to the drug's target. Drugs cannot effectively treat cancers caused by mutations downstream of their target proteins.
17. A constitutively active mutant of a Receptor Tyrosine Kinase (RTK) is created that dimerizes even in the absence of a ligand. However, this mutant fails to activate the downstream MAPK pathway. Further analysis shows that while its kinase domain is functional, key tyrosine residues in its own cytoplasmic tail have been mutated to phenylalanine. What is the most likely biochemical explanation for this lack of signaling?
    Answer: The absence of phosphotyrosine residues prevents the recruitment of adaptor proteins containing SH2 domains, such as Grb2. The correct answer is B. RTK activation requires autophosphorylation on specific tyrosine residues in the cytoplasmic tail. These phosphotyrosine sites act as docking points for proteins with SH2 (Src Homology 2) or PTB domains, such as the adaptor protein Grb2. Mutating these tyrosines to phenylalanine, which cannot be phosphorylated, eliminates these docking sites. Even though the kinase is active and can dimerize, it cannot recruit the necessary downstream components to propagate the signal. Choice A is incorrect because the stem states the kinase domain is functional, implying it can bind ATP. Choice C is incorrect as phenylalanine does not mimic phosphotyrosine; acidic residues like aspartate or glutamate are used for that purpose. Choice D is incorrect because the problem is a failure to initiate the signal via phosphorylation, not a failure to terminate it via dephosphorylation.
18. A mutation in the adaptor protein Grb2 prevents its binding to phosphorylated RTK tyrosine residues but does not affect its ability to bind to SOS (the guanine nucleotide exchange factor). If cells expressing this mutant Grb2 are stimulated with growth factors, what would be the most likely consequence for MAPK pathway activation?
    Answer: Severely impaired MAPK activation occurs because Grb2 cannot be recruited to activated RTKs, preventing the formation of RTK-Grb2-SOS complexes necessary for Ras activation at the membrane. When approaching MAPK pathway questions, focus on the sequential steps required for signal transduction from the membrane to the nucleus. The RTK-Grb2-SOS complex formation is absolutely critical for proper Ras activation. The mutant Grb2 creates a fatal break in the signaling chain. While it can still bind SOS, it cannot attach to phosphorylated RTK tyrosine residues. This means that when growth factors bind to RTKs and cause receptor autophosphorylation, the Grb2-SOS complex cannot be recruited to the membrane where Ras is located. Since Ras must be activated at the membrane (where it's anchored), SOS needs to be brought there via the RTK-Grb2 bridge. Without this recruitment mechanism, SOS remains cytosolic and cannot exchange GDP for GTP on Ras, severely blocking MAPK activation. Option A is wrong because alternative membrane recruitment mechanisms for Grb2 don't exist when its RTK-binding domain is defective. Option B incorrectly assumes sufficient compensatory mechanisms exist - while other adaptors like Shc exist, they don't fully compensate for Grb2 loss. Option C misunderstands the mutation's effect; the Grb2-SOS interaction isn't constitutively active, and without membrane recruitment, this binding is actually detrimental since it sequesters SOS away from Ras. Remember that signal transduction pathways require proper subcellular localization. A functional domain mutation doesn't just reduce efficiency - it can completely break essential protein-protein interactions that enable spatial organization of signaling complexes.

Start this quiz